Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Big Pharmas slash cancer drug prices again for Chinese insurance
Wednesday, October 10, 2018
Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Takeda's Alunbrig bests Xalkori in untreated ALK+ lung cancer
Wednesday, July 25, 2018
Takeda's Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche—but some new data could help change that.
Pfizer's Xalkori picks up two new FDA 'breakthrough' tags
Tuesday, May 29, 2018
Pfizer's Xalkori has picked up two FDA breakthrough designations, one for certain lung cancer patients and another in a rare form of lymphoma.
16 blockbuster nods in 2018's China: report
Friday, January 5, 2018
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
Roche's Alecensa scores new lung cancer approval
Tuesday, November 7, 2017
Roche's Alecensa nabbed a new FDA approval to treat first-line lung cancer, putting it on even footing with Pfizer's Xalkori and Novartis' Zykadia.
Novartis' Zykadia pressures Pfizer, Roche with new NSCLC nod
Tuesday, May 30, 2017
Pfizer’s Xalkori will have to move over in ALK-positive lung cancer. Novartis’ Zykadia now has FDA approval to go head-to-head in previously untreated patients
Takeda picks up FDA approval for potential blockbuster Alunbrig
Friday, April 28, 2017
Two months after snapping up Ariad, Takeda is getting a quick return. The Ariad-developed potential blockbuster Alunbrig won FDA approval Friday.
Roche's Alecensa beats Xalkori in quest for expanded market
Tuesday, April 11, 2017
Roche’s Alecensa topped Pfizer’s Xalkori in previously untreated ALK+ lung cancer, setting it up for a potential showdown with Pfizer and Novartis.
Novartis' Zykadia gets a boost in lung cancer race against Roche
Friday, February 24, 2017
Novartis isn’t letting its crosstown rival get all the regulatory attention when it comes to ALK+ metastatic non-small cell lung cancer.